Published in Medical Letter on the CDC and FDA, January 23rd, 2005
"A targeted library of small molecules has been prepared to optimize the biological activity of BN82002, our initial lead compound, recently described as an original inhibitor of CDC25 phosphatases," researchers in France report.
"Some of these compounds inhibit CDC25 in the micromolar range and therefore reinforce the interest of CDC25 as an anticancer target," wrote Marie-Odile Contour-Galcera and colleagues at the Institut Henri Beaufour.
Contour-Galcera and associates published their study in Bioorganic and Medicinal Chemistry Letters...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA